FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004199519> ?p ?o ?g. }

• W2004199519 abstract "Abstract Background Bleeding severity, anatomic location, tissue characteristics, and visibility are common challenges encountered while managing intraoperative bleeding, and conventional hemostatic measures (suture, ligature, and cautery) may sometimes be ineffective or impractical. While topical absorbable hemostats (TAH) are useful hemostatic adjuvants, each TAH has associated disadvantages. Methods We evaluated the safety and hemostatic efficacy of a new advanced biologic combination product―fibrin pad―to potentially address some gaps associated with TAHs. Fibrin pad was assessed as adjunctive hemostat in open partial nephrectomy in single-center, open-label, Phase I study (N = 10), and as primary hemostat in multicenter, single-blind, randomized, standard-of-care (SOC)-controlled Phase I/II study (N = 7) in Israel. It was used to control mild-to-moderate bleeding in Phase I and also spurting arterial bleeding in Phase I/II study. Phase I study assessed safety and Phase I/II study, proportion of successes at 10 min following randomization, analyzed by Fisher exact tests at 5% significance level. Results Phase I (N = 10): All patients completed the study. Hemostasis was achieved within 3–4 min (average = 3.1 min) of a single application in all patients. Fibrin pad was found to be safe for human use, with no product-related adverse events reported. Phase I/II (N = 7): Hemostatic success at 10 min (primary endpoint) was achieved in 3/4 patients treated with fibrin pad versus 0/3 patients treated with SOC. No clinically significant change in laboratory or coagulation parameters was recorded, except a case of post-procedural hemorrhage with fibrin pad, which was considered serious and related to the fibrin pad treatment, and required re-operation. Although Data Safety Monitoring Board authorized trial continuation, the sponsor decided against proceeding toward an indication for primary treatment of severe arterial hemorrhage as a replacement for sutures. The study was suspended after 7/30 planned subjects were enrolled. Conclusions The first-in-man trial of fibrin pad demonstrated its safety and efficacy as an adjunctive hemostatic technique for mild-to-moderate bleeding in partial nephrectomy. The study also suggested that the product should not replace sutures or meticulous surgical techniques for the treatment of severe arterial hemorrhage. Trial registration Phase I/II trial, NCT00598130" @default.
• W2004199519 created "2016-06-24" @default.
• W2004199519 creator A5017895853 @default.
• W2004199519 creator A5032584176 @default.
• W2004199519 creator A5036419071 @default.
• W2004199519 creator A5046129039 @default.
• W2004199519 creator A5069730408 @default.
• W2004199519 creator A5078937071 @default.
• W2004199519 date "2012-11-08" @default.
• W2004199519 modified "2023-10-14" @default.
• W2004199519 title "Safety and hemostatic efficacy of fibrin pad in partial nephrectomy: Results of an open-label Phase I and a randomized, standard-of-care-controlled Phase I/II study" @default.
• W2004199519 cites W1913369396 @default.
• W2004199519 cites W1967420220 @default.
• W2004199519 cites W1980529203 @default.
• W2004199519 cites W1993741366 @default.
• W2004199519 cites W1994604939 @default.
• W2004199519 cites W1996859731 @default.
• W2004199519 cites W2005625497 @default.
• W2004199519 cites W2015200163 @default.
• W2004199519 cites W2018042896 @default.
• W2004199519 cites W2019179832 @default.
• W2004199519 cites W2028012698 @default.
• W2004199519 cites W2029354415 @default.
• W2004199519 cites W2039166189 @default.
• W2004199519 cites W2050960519 @default.
• W2004199519 cites W2052978122 @default.
• W2004199519 cites W2085455534 @default.
• W2004199519 cites W2094548442 @default.
• W2004199519 cites W2107949404 @default.
• W2004199519 cites W2113375334 @default.
• W2004199519 cites W2114659602 @default.
• W2004199519 cites W2140020334 @default.
• W2004199519 cites W2145632027 @default.
• W2004199519 cites W2149044173 @default.
• W2004199519 cites W2151546172 @default.
• W2004199519 cites W2161671729 @default.
• W2004199519 cites W2167696535 @default.
• W2004199519 cites W4360754122 @default.
• W2004199519 doi "https://doi.org/10.1186/1471-2369-13-147" @default.
• W2004199519 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3519604" @default.
• W2004199519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23137020" @default.
• W2004199519 hasPublicationYear "2012" @default.
• W2004199519 type Work @default.
• W2004199519 sameAs 2004199519 @default.
• W2004199519 citedByCount "10" @default.
• W2004199519 countsByYear W20041995192014 @default.
• W2004199519 countsByYear W20041995192015 @default.
• W2004199519 countsByYear W20041995192016 @default.
• W2004199519 countsByYear W20041995192020 @default.
• W2004199519 countsByYear W20041995192023 @default.
• W2004199519 crossrefType "journal-article" @default.
• W2004199519 hasAuthorship W2004199519A5017895853 @default.
• W2004199519 hasAuthorship W2004199519A5032584176 @default.
• W2004199519 hasAuthorship W2004199519A5036419071 @default.
• W2004199519 hasAuthorship W2004199519A5046129039 @default.
• W2004199519 hasAuthorship W2004199519A5069730408 @default.
• W2004199519 hasAuthorship W2004199519A5078937071 @default.
• W2004199519 hasBestOaLocation W20041995191 @default.
• W2004199519 hasConcept C126322002 @default.
• W2004199519 hasConcept C141071460 @default.
• W2004199519 hasConcept C168563851 @default.
• W2004199519 hasConcept C197934379 @default.
• W2004199519 hasConcept C203014093 @default.
• W2004199519 hasConcept C203092338 @default.
• W2004199519 hasConcept C204243189 @default.
• W2004199519 hasConcept C2777552930 @default.
• W2004199519 hasConcept C2778589496 @default.
• W2004199519 hasConcept C2780091579 @default.
• W2004199519 hasConcept C2780227381 @default.
• W2004199519 hasConcept C2909810335 @default.
• W2004199519 hasConcept C2910835652 @default.
• W2004199519 hasConcept C54173615 @default.
• W2004199519 hasConcept C71924100 @default.
• W2004199519 hasConceptScore W2004199519C126322002 @default.
• W2004199519 hasConceptScore W2004199519C141071460 @default.
• W2004199519 hasConceptScore W2004199519C168563851 @default.
• W2004199519 hasConceptScore W2004199519C197934379 @default.
• W2004199519 hasConceptScore W2004199519C203014093 @default.
• W2004199519 hasConceptScore W2004199519C203092338 @default.
• W2004199519 hasConceptScore W2004199519C204243189 @default.
• W2004199519 hasConceptScore W2004199519C2777552930 @default.
• W2004199519 hasConceptScore W2004199519C2778589496 @default.
• W2004199519 hasConceptScore W2004199519C2780091579 @default.
• W2004199519 hasConceptScore W2004199519C2780227381 @default.
• W2004199519 hasConceptScore W2004199519C2909810335 @default.
• W2004199519 hasConceptScore W2004199519C2910835652 @default.
• W2004199519 hasConceptScore W2004199519C54173615 @default.
• W2004199519 hasConceptScore W2004199519C71924100 @default.
• W2004199519 hasIssue "1" @default.
• W2004199519 hasLocation W20041995191 @default.
• W2004199519 hasLocation W20041995192 @default.
• W2004199519 hasLocation W20041995193 @default.
• W2004199519 hasLocation W20041995194 @default.
• W2004199519 hasOpenAccess W2004199519 @default.
• W2004199519 hasPrimaryLocation W20041995191 @default.
• W2004199519 hasRelatedWork W1486816417 @default.
• W2004199519 hasRelatedWork W168918734 @default.
• W2004199519 hasRelatedWork W1971224117 @default.
• W2004199519 hasRelatedWork W2051367795 @default.
• W2004199519 hasRelatedWork W2100932347 @default.

• next